Back to top

Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Supernus Pharmaceuticals, with a price target of $66.00. A...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Supernus Pharmaceuticals, Inc. (SUPN)